Русский | Deutsch | Italiano | English | Español | Français

Colorado Country Store – Deli, Butcher and Coffee Bar

The two brand new pharmaceutical pain relievers will probably be marketed as transdermal adhesive patches that deliver a certain dose of medication into the blood by absorption via the patient’s skin.
Transdermal drug delivery routes have the capacity to promote recovery of an injured area of the body. This shipping method may be superior to other varieties of medication delivery, including topical, oral, intravenous, intramuscular,and many others, due to the further control over the dosage administered to the patient.
The patch provides a more controlled release of the medication, either via having a sterile membrane to allow the medication be absorbed gradually by your skin, or via embedding thin layers of the medication in the adhesive that melt together with the patient’s body heat.
Cannabinoids have an extensive record of medicinal uses, dating back a long time.

At present, several peer-reviewed scientific publications are documenting the inherent biochemical pathways that cannabinoids modulate.
These patches will contain high effectiveness cannabinoid (CBD) extract, the second major cannabinoid in marijuana following THC (tetrahydrocannabinol). The extract gradually enters the blood then penetrates an individual ‘s central nervous system to work as a pain reliever.
CBD has anti-inflammatory and pain-relieving properties with no known psychoactive results.

Research has demonstrated that CBD may be an effective treatment for several kinds of pain, especially inflammatory pain. Some studies have also shown that CBD might pain outperform traditional medication when treating inflammatory illness.
"While we attempt to maximize our territory capacity for expansion and centers to create our own product to supply our scientists with proprietary materials to create these formulations, we are also busy researching more possible demands for Cannabis related medical programs and developing the methods for delivery of those medicines," Raymond C. Dabney, Cannabis Science CEO stated in a press release.
"As more states nationwide [from the U.S.] legislate to the legalization of cannabis and cannabis-derived medicines, we here in Cannabis Science are focused on developing pharmaceutical formulations and applications to supply the enormous growing demand anticipated over the coming couple of decades," Dabney said.

Fibromyalgia is estimated to affect 2%-8% of the population.

Posts Similares:

  • Digg
  • Facebook
  • Google Bookmarks
  • email
  • LinkedIn
  • MySpace
  • Scoopeo
  • Technorati
  • Wikio FR
  • connotea

Laisser un commentaire

bot © 2019 CoPeerRight Agency. FAQ | Conditions d'utilisation | Mentions légales